Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

Summary

In a 72-week, double-blind phase 3 RCT of 3127 adults with obesity, orforglipron produced dose-dependent weight loss up to −11.2% (36 mg) versus −2.1% with placebo, with significant improvements in waist circumference, systolic BP, triglycerides, and non-HDL cholesterol. Gastrointestinal events were the most common adverse events, generally mild to moderate, with discontinuations in 5.3–10.3% across orforglipron doses.

Key Findings

• Mean weight change at 72 weeks: −7.5% (6 mg), −8.4% (12 mg), −11.2% (36 mg) vs −2.1% with placebo (P<0.001).
• At 36 mg, 54.6%, 36.0%, and 18.4% achieved ≥10%, ≥15%, and ≥20% weight loss, respectively, vs 12.9%, 5.9%, and 2.8% with placebo.
• Waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol improved significantly versus placebo.

Clinical Implications

Oral GLP-1RA therapy may become a practical first-line or adjunct option for obesity management, particularly for patients preferring pills or with injection barriers; monitoring for GI tolerability and tailoring dose is important.

Limitations

• Placebo comparator without active GLP-1RA head-to-head comparison.
• Population excluded diabetes; generalizability to people with T2D requires dedicated trials.

Future Directions

Head-to-head trials versus established injectable incretin therapies, evaluation in T2D and comorbid populations, and long-term cardiovascular outcomes and safety studies.